| Dr Orlando C Kirton, MD | |
|
1245 Highland Ave Ste 302, Abington, PA 19001-3724 | |
| (215) 481-7462 | |
| Not Available |
| Full Name | Dr Orlando C Kirton |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 41 Years |
| Location | 1245 Highland Ave Ste 302, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649384967 | NPI | - | NPPES |
| 001375682 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | 037568 (Connecticut) | Secondary |
| 2086S0102X | Surgery - Surgical Critical Care | MD458795 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abington Memorial Hospital | Abington, PA | Hospital |
| Abington Health Lansdale Hospital | Lansdale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Surgical Care Specialists Inc | 5597747154 | 14 |
News Archive
The money will help to create the country's first ever Mental Health Research Network, which will act as a central resource and help to co-ordinate research.
People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.
For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, announces a strategic collaboration with Touch Surgery to help improve patient outcomes by delivering simulated surgical training based on the safe and efficacious use of Ethicon products in a free mobile app that can reach medical professionals in even remote regions of the world.
› Verified 2 days ago
| Entity Name | Surgical Care Specialists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346386398 PECOS PAC ID: 5597747154 Enrollment ID: O20040607000497 |
News Archive
The money will help to create the country's first ever Mental Health Research Network, which will act as a central resource and help to co-ordinate research.
People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.
For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, announces a strategic collaboration with Touch Surgery to help improve patient outcomes by delivering simulated surgical training based on the safe and efficacious use of Ethicon products in a free mobile app that can reach medical professionals in even remote regions of the world.
› Verified 2 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1528403904 PECOS PAC ID: 3274437736 Enrollment ID: O20130923000282 |
News Archive
The money will help to create the country's first ever Mental Health Research Network, which will act as a central resource and help to co-ordinate research.
People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.
For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, announces a strategic collaboration with Touch Surgery to help improve patient outcomes by delivering simulated surgical training based on the safe and efficacious use of Ethicon products in a free mobile app that can reach medical professionals in even remote regions of the world.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Orlando C Kirton, MD 1245 Highland Ave Ste 302, Abington, PA 19001-3724 Ph: (215) 481-7462 | Dr Orlando C Kirton, MD 1245 Highland Ave Ste 302, Abington, PA 19001-3724 Ph: (215) 481-7462 |
News Archive
The money will help to create the country's first ever Mental Health Research Network, which will act as a central resource and help to co-ordinate research.
People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.
For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, announces a strategic collaboration with Touch Surgery to help improve patient outcomes by delivering simulated surgical training based on the safe and efficacious use of Ethicon products in a free mobile app that can reach medical professionals in even remote regions of the world.
› Verified 2 days ago
Hamzeh Moh'd Adeeb Halawani, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-441-6800 | |
Dr. James Victor Yuschak, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1245 Highland Ave, Abington, PA 19001 Phone: 215-887-3990 | |
Dr. Theodore Robert Sullivan, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1245 Highland Ave, Suite 600, Abington, PA 19001 Phone: 215-887-3990 Fax: 215-887-1140 | |
Mr. Michael Lynn Nussbaum, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1245 Highland Ave, Suite 600, Abington, PA 19001 Phone: 215-887-3990 Fax: 215-887-1140 | |
Emmanuel Melonakos, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2606 | |
Dr. Ryan Marc Shadis, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1245 Highland Avenue, Suite 600, Abington, PA 19001 Phone: 215-887-3990 Fax: 215-887-1140 | |
Dr. Linda Li, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-7464 |